• 1. Aggregation behaviour of biocompatible choline carboxylate ionic liquids and their interactions with biomolecules through experimental and theoretical investigations?
  Somenath Panda,Kaushik Kundu,Anusha Basaiahgari,Sanjib Senapati,Ramesh L. Gardas New J. Chem., 2018,42, 7105-7118
• 2. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to 1-methylindazole-5-carbonitrile (CAS No. 189107-45-7)

1-methylindazole-5-carbonitrile, identified by the Chemical Abstracts Service Number (CAS No.) 189107-45-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the indazole family, a class of molecules known for their diverse biological activities and potential therapeutic applications. The structural features of 1-methylindazole-5-carbonitrile, particularly the presence of a methyl group at the 1-position and a nitrile group at the 5-position, contribute to its unique chemical properties and reactivity, making it a valuable scaffold for drug discovery and development.

The indazole core is a fused bicyclic system consisting of a benzene ring and a pyrrole ring, which is commonly found in numerous bioactive natural products and pharmacologically relevant compounds. The introduction of the nitrile group at the 5-position introduces a polar, electron-withdrawing moiety that can influence both the electronic distribution and steric environment of the molecule. This modification can enhance binding affinity to biological targets, modulate metabolic stability, and influence pharmacokinetic profiles, all of which are critical factors in drug design.

In recent years, there has been growing interest in indazole derivatives due to their demonstrated efficacy in various therapeutic areas, including anticancer, anti-inflammatory, and antimicrobial applications. The nitrile-substituted indazoles have shown particular promise as inhibitors of key enzymes and pathways involved in disease progression. For instance, studies have highlighted the potential of 1-methylindazole-5-carbonitrile as a lead compound in the development of novel antitumor agents. The nitrile group has been shown to enhance interactions with nucleophilic residues in target proteins, potentially leading to increased potency and selectivity.

One of the most compelling aspects of 1-methylindazole-5-carbonitrile is its versatility as a chemical building block. The presence of both the methyl and nitrile functional groups provides multiple sites for further chemical modification, allowing medicinal chemists to explore a wide range of derivatives with tailored properties. This flexibility is particularly valuable in structure-activity relationship (SAR) studies, where subtle changes in the molecular structure can significantly impact biological activity.

Recent advancements in synthetic methodologies have enabled more efficient and scalable production of 1-methylindazole-5-carbonitrile, making it more accessible for research purposes. Techniques such as transition-metal-catalyzed cross-coupling reactions and microwave-assisted synthesis have improved yields and reduced reaction times, facilitating faster discovery and optimization processes. These innovations are crucial for accelerating the development of new drugs based on this promising scaffold.

The pharmacological profile of 1-methylindazole-5-carbonitrile has been extensively studied in both in vitro and in vivo models. Preliminary findings suggest that this compound exhibits inhibitory activity against several enzymes implicated in cancer metabolism, such as poly(ADP-ribose) polymerase (PARP) inhibitors. Additionally, its ability to modulate inflammatory pathways has been explored, with early results indicating potential benefits in treating chronic inflammatory diseases.

The synthesis of 1-methylindazole-5-carbonitrile involves multi-step organic transformations that highlight its complexity as a molecular entity. Key synthetic steps typically include cyclization reactions to form the indazole core, followed by functional group interconversions to introduce the methyl and nitrile groups at appropriate positions. Advances in computational chemistry have also played a significant role in predicting optimal synthetic routes and predicting the properties of newly synthesized compounds.

In conclusion, 1-methylindazole-5-carbonitrile (CAS No. 189107-45-7) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activities. Its role as a versatile scaffold for drug discovery underscores its importance in ongoing research efforts aimed at developing novel therapeutic agents. As synthetic methodologies continue to evolve and our understanding of biological targets deepens, compounds like 1-methylindazole-5-carbonitrile are poised to play a crucial role in addressing unmet medical needs.

• 267413-31-0(1-Methyl-1H-indazole-6-methanamine)
• 267413-29-6(1-methylindazole-6-carbonitrile)
• 267413-27-4((1-methyl-1H-indazol-5-yl)methanamine)
• 34879-87-3(1H-Indazole, 1,6-dimethyl-)
• 838820-84-1(Benzonitrile, 4-(1H-indazol-1-yl)-)
• 256228-68-9(1-Methyl-1H-indazole-7-carbonitrile)
• 1159511-43-9(1-Methyl-1H-indazole-4-carbonitrile)
• 1159511-45-1(2-methyl-2H-indazole-4-carbonitrile)
• 1015846-71-5(1,5-Dimethyl-1H-indazole-3-carbonitrile)
• 1125409-65-5(1-Benzyl-1H-indazole-5-carbonitrile)